Nonmotor features of Parkinson's disease subtypes

Movement Disorders

Volumn 31, Issue 8, 2016, Pages 1095-1102

  Marras, Connie ^a   Chaudhuri, K Ray ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

nonmotor symptoms; Parkinson's disease; prognosis; subtypes

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; DOPAMINE; IRON; SYNUCLEIN;

AKINESIA; ANOSMIA; ANXIETY; APATHY; ARTICLE; AUTONOMIC DYSFUNCTION; BODY POSTURE; CLINICAL FEATURE; CLINICAL OBSERVATION; COGNITIVE DEFECT; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE CLASSIFICATION; DISEASE DURATION; DYSAUTONOMIA; FATIGUE; HUMAN; HYPERSALIVATION; IMPULSE CONTROL DISORDER; LEWY BODY; MILD COGNITIVE IMPAIRMENT; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROIMAGING; NEUROLOGIC GAIT DISORDER; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; TREMOR; URINARY DYSFUNCTION; WITHDRAWAL SYNDROME; AUTONOMIC NEUROPATHY; CLASSIFICATION; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY;

AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; GAIT DISORDERS, NEUROLOGIC; HUMANS; PARKINSON DISEASE; TREMOR;

EID: 84981276418     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26510     Document Type: Article

References (68)

1. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord 2016;22(Suppl 1):S41-S46.
2. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
3. Schiess MC, Zheng H, Soukup VM, Bonnen JG, Nauta HJ. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord 2000;6:69-76.
4. Geurtsen GJ, Hoogland J, Goldman JG, et al. Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis 2014;4:131-137.
5. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.
6. Zis P, Martinez-Martin P, Sauerbier A, et al. Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. Eur J Neurol 2015;22:1145-1150.
7. Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord 2009;24(Suppl 2):S656-S664.
8. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613-634.
9. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
10. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. Mov Disord 2012;27:716-719.
11. Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR. The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review. Nature Parkinson's Journal (NPJ) Parkinson's disease 2015;1:15013.
12. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30.
13. Halliday G, Lees A, Stern M. Milestones in Parkinson's disease--clinical and pathologic features. Mov Disord 2011;26:1015-1021.
14. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-2957.
15. Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. Mov Disord 2014;29:1710-1719.
16. Dujardin K, Defebvre L, Duhamel A, et al. Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol 2004;251:1383-1392.
17. Gasparoli E, Delibori D, Polesello G, et al. Clinical predictors in Parkinson's disease. Neurol Sci 2002;23(Suppl 2):S77-S78.
18. Graham JM, Sagar HJ. A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. Mov Disord 1999;14:10-20.
19. Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-348.
20. Liu P, Feng T, Wang YJ, et al. Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis. J Zhejiang Univ Sci B 2011;12:694-703.
21. Post B, Speelman JD, de Haan RJ, et al. Clinical heterogeneity in newly diagnosed Parkinson's disease. J Neurol 2008;255:716-722.
22. Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:379-382.
23. Schrag A, Quinn NP, Ben-Shlomo Y. Heterogeneity of Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:275-276.
24. van Rooden SM, Visser M, Verbaan D, et al. Motor patterns in Parkinson's disease: a data-driven approach. Mov Disord 2009;24:1042-1047.
25. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. The Lancet Neurol 2009;8:464-474.
26. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
27. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29:1010-1018.
28. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010;6:309-317.
29. Schrag A, Choudhury M, Kaski D, Gallagher DA. Why do patients with Parkinson's disease fall? A cross-sectional analysis of possible causes of falls. Npj Parkinson's Disease 2015;1:15011.
30. Kasten M, Klein C. Non-motor signs in genetic forms of Parkinson's disease. In: Ray Chaudhuri K TE, Schapira AHV, Poewe W, eds. Non Motor Symptoms of Parkinson's Disease Oxford: Oxford University Press; 2014:92-124.
31. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406.
32. Politis M, Wu K, Molloy S, P GB, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010;25:1646-1651.
33. Chaudhuri KR, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One [Electronic Resource] 2013.
34. Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013;80:276-281.
35. Muller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord 2011;26:65-72.
36. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015;30:229-237.
37. Herman T, Weiss A, Brozgol M, Wilf-Yarkoni A, Giladi N, Hausdorff JM. Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes. J Neural Transm (Vienna) 2015;122:1115-1124.
38. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 2009;73:206-212.
39. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
40. Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinson's disease subtypes. Neurology 1994;44:266-268.
41. Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008;70:1403-1410.
42. Selikhova M, Kempster PA, Revesz T, Holton JL, Lees AJ. Neuropathological findings in benign tremulous Parkinsonism. Mov Disord 2013;28:145-152.
43. Eggers C, Schwartz F, Pedrosa DJ, Kracht L, Timmermann L. Parkinson's disease subtypes show a specific link between dopaminergic and glucose metabolism in the striatum. PLoS One 2014;9.
44. Prodoehl J, Planetta PJ, Kurani AS, Comella CL, Corcos DM, Vaillancourt DE. Differences in brain activation between tremor- and nontremor-dominant Parkinson disease. JAMA Neurol 2013;70:100-106.
45. Mure H, Hirano S, Tang CC, et al. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 2011;54:1244-1253.
46. Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Toni I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol 2011;69:269-281.
47. Bunzeck N, Singh-Curry V, Eckart C, et al. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism Relat Disord 2013;19:1136-1142.
48. Jin L, Wang J, Jin H, et al. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease. Eur J Neurol 2012;19:969-976.
49. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
50. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011;122:187-204.
51. Alves G, Pedersen KF, Bloem BR, et al. Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:537-543.
52. Saiki S, Hirose G, Sakai K, et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 2004;220:105-111.
53. Spiegel J, Hellwig D, Farmakis G, et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 2007;22:1004-1008.
54. Von Coelln FR, Barr E, Gruber-Baldini A, Reich S, Armstrong MJ, Shulman L. Motor Subtypes of Parkinson Disease Are Unstable Over Time. Neurology April 6, 2015; Vol. 84 No. 14 Supplement S48002 2015;84:S48.002.
55. de Lau LM, Verbaan D, van Rooden SM, Marinus J, van Hilten JJ. Relation of clinical subtypes in Parkinson's disease with survival. Mov Disord 2014;29:150-151.
56. van Rooden SM, Heiser WJ, Kok JN, et al. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 2010;25:969-978.
57. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-923.
58. Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS One [Electronic Resource] 2013;8:e70244.
59. Erro R, Picillo M, Amboni M, et al. Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. Mov Disord 2015;30:373-378.
60. Romenets SR, Gagnon JF, Latreille V, et al. Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. Mov Disord 2012;27:996-1003.
61. Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. Parkinsonism Relat Disord 2010;16:252-255.
62. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015;72:863-873.
63. Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord 2015;30:919-927.
64. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.
65. Brown RG, Landau S, Hindle JV, et al. Depression and anxiety related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82:803-809.
66. Burn DJ, Landau S, Hindle JV, et al. Parkinson's disease motor subtypes and mood. Mov Disord 2012;27:379-386.
67. Dujardin K, Langlois C, Plomhause L, et al. Apathy in untreated early-stage Parkinson disease: Relationship with other non-motor symptoms. Mov Disord 2014;29:1796-1801.
68. Sharma JC, Vassallo M. Prognostic significance of weight changes in Parkinson's disease: the Park-weight phenotype. Neurodegener Dis Manag 2014;4:309-316.